EAGAN, Minn.--(BUSINESS WIRE)--Biothera’s Phase II non-small cell lung cancer (NSCLC) clinical trial evaluating Imprime PGG® administered in combination with cetuximab (Erbitux®), carboplatin and paclitaxel has met its goal of 90 patients and is fully enrolled, the company announced today.
